Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28745643 | 0.96 | NPC1 (0.69) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| Diethylamine SCHEMBL4493585 | 0.89 | NPC1 (0.60) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9834670 | 0.87 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3878827 | 0.86 | NPC1 (0.55) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL899098 | 0.86 | NPC1 (0.59) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8536799 | 0.84 | NPC1 (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1326529 | 0.84 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3903274 | 0.84 | NPC1 (0.71) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24663122 | 0.83 | ALDH1A1 (0.54) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8507040 | 0.83 | ALDH1A1 (0.63) | NPC1RAB9AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746885-A2 | ACTIVATING PIEZO1 AND PIEZO2 CHANNELS FOR NEUROPROTECTION AND AXON REGENERATION IN THE RETINA AND OPTIC NERVE | The Board of Trustees of The Leland Stanford Junior University (US) | 2026-05-27 | — | — | EP | claimed |
| US-20250368955-A1 | B CELL LINEAGES DERIVED FROM PLURIPOTENT CELLS | STRATUS THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250368954-A1 | MYELOID LINEAGES DERIVED FROM PLURIPOTENT CELLS | STRATUS THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250361487-A1 | NATURAL KILLER CELL LINEAGES DERIVED FROM PLURIPOTENT CELLS | STRATUS THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4598552-A1 | B CELL LINEAGES DERIVED FROM PLURIPOTENT CELLS | Garuda Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4599051-A2 | ERYTHROID LINEAGES DERIVED FROM PLURIPOTENT CELLS | Garuda Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4599055-A1 | MODIFIED HEMATOPOIETIC STEM CELLS AND PROGENIES THEREOF | Garuda Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4599046-A1 | IMMUNE COMPATIBLE CELLS FOR ALLOGENEIC CELL THERAPIES TO COVER GLOBAL, ETHNIC, OR DISEASE-SPECIFIC POPULATIONS | Garuda Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| WO-2025019150-A2 | ACTIVATING PIEZO1 AND PIEZO2 CHANNELS FOR NEUROPROTECTION AND AXON REGENERATION IN THE RETINA AND OPTIC NERVE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-23 | — | — | WO | claimed |
| CN-119055770-A | Use of Piezo1 agonist in preparation of medicament for treating Ma Fanzeng syndrome | 武汉市中心医院（武汉市第二医院、武汉市肿瘤研究所） | 2024-12-03 | — | — | CN | claimed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| JP-2009520720-A | — | — | 2009-05-28 | — | — | JP | claimed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | claimed |
| EP-1989174-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| WO-2007079930-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | NPC1 2369/4885RAB9A 916/4885ALDH1A1 1630/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | NPC1 2440/4885RAB9A 1045/4885ALDH1A1 1575/4885 |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | NPC1 112/4885RAB9A 905/4885ALDH1A1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.